Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
ALTEOGEN signed an exclusive license agreement worth up to USD 365M (approx. KRW 521.9B) to develop and commercialize a subcutaneous (SC) formulation for one target product using its recombinant human hyaluronidase platform (ALT-B4).
📊 [Key Disclosure Details & Major Figures Summary]
- Agreement Title: Exclusive License Agreement for Recombinant Human Hyaluronidase Product ALT-B4
- Contracting Party: Undisclosed (Withheld due to confidentiality obligations and business competitiveness protection)
- Contract Details: Exclusive license to develop and commercialize one partner target product into a subcutaneous (SC) formulation using ALTEOGEN’s Hybrozyme technology (ALT-B4)
- Execution Date / Period: August 04, 2026 / August 05, 2026 – Expiration of royalty period
- Financial Terms (Applied Exchange Rate: KRW 1,429.90/USD):
- Upfront & Milestones: Up to USD 365,000,000 (Approx. KRW 521.9B)
- Sales Royalties: Royalties based on a percentage of net sales after first commercial launch (Separate from milestones)
- Refund Obligation: Non-refundable (Upfront, milestones, and royalties received are non-refundable)
- Upfront Payment Timeline: Scheduled for receipt within 30 days from the effective date (August 05, 2026)
- Investment Risk Considerations: Conditional agreement subject to regulatory approvals; revenue realization depends on clinical trials and approval outcomes, and the contract may terminate or payments decrease in case of clinical failure or halting
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Verification of Upfront Payment Inflow and Clinical/Commercial Milestone Progress
This agreement consists of an upfront payment due within 30 days of the effective date and development/commercialization milestones. Verifying the timely receipt of the upfront payment and tracking progress on subsequent clinical milestones is essential because it allows investors to confirm the actual financial realization and earnings recognition schedule from this technology licensing agreement. Detailed progress can be cross-checked in subsequent periodic reports (Quarterly, Half-Yearly, and Annual Reports) and related disclosure filings.
📢 Disclaimer & Source Notice
Source: This content has been structured and newly created based on official filing data from the Financial Supervisory Service (DART).
Investment Risk Notice: This content is provided for informational and language reference purposes only. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any specific stock. All investment decisions and financial responsibilities rest entirely with the investor.
Contact: For compliance inquiries or copyright requests, please contact ksb220805@gmail.com.
